622 related articles for article (PubMed ID: 28500560)
21. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
[TBL] [Abstract][Full Text] [Related]
22. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
Colaco RJ; Martin P; Kluger HM; Yu JB; Chiang VL
J Neurosurg; 2016 Jul; 125(1):17-23. PubMed ID: 26544782
[TBL] [Abstract][Full Text] [Related]
23. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies.
Kim JM; Miller JA; Kotecha R; Xiao R; Juloori A; Ward MC; Ahluwalia MS; Mohammadi AM; Peereboom DM; Murphy ES; Suh JH; Barnett GH; Vogelbaum MA; Angelov L; Stevens GH; Chao ST
J Neurooncol; 2017 Jun; 133(2):357-368. PubMed ID: 28434110
[TBL] [Abstract][Full Text] [Related]
24. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK
Melanoma Res; 2016 Aug; 26(4):387-94. PubMed ID: 27223498
[TBL] [Abstract][Full Text] [Related]
25. Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
Jablonska PA; Muniz T; Ribeiro M; Liu ZA; Ye XY; Devaraja K; Laperriere N; Millar BA; Conrad T; Kongkham P; Butler M; Shultz DB
J Neurooncol; 2023 Aug; 164(1):199-209. PubMed ID: 37552363
[TBL] [Abstract][Full Text] [Related]
26. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
[TBL] [Abstract][Full Text] [Related]
28. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA
Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227
[TBL] [Abstract][Full Text] [Related]
30. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
[TBL] [Abstract][Full Text] [Related]
31. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
Schapira E; Hubbeling H; Yeap BY; Mehan WA; Shaw AT; Oh K; Gainor JF; Shih HA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):624-629. PubMed ID: 29678530
[TBL] [Abstract][Full Text] [Related]
32. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
[TBL] [Abstract][Full Text] [Related]
33. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response.
Yusuf MB; Amsbaugh MJ; Burton E; Chesney J; Woo S
World Neurosurg; 2017 Apr; 100():632-640.e4. PubMed ID: 28179176
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.
Carron R; Gaudy-Marqueste C; Amatore F; Padovani L; Malissen N; Balossier A; Loundou A; Bonnet N; Muracciole X; Régis JM; Grob JJ
Eur J Cancer; 2020 Aug; 135():52-61. PubMed ID: 32535348
[TBL] [Abstract][Full Text] [Related]
35. Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis.
Miller JA; Bennett EE; Xiao R; Kotecha R; Chao ST; Vogelbaum MA; Barnett GH; Angelov L; Murphy ES; Yu JS; Ahluwalia MS; Suh JH; Mohammadi AM
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1060-1069. PubMed ID: 27742540
[TBL] [Abstract][Full Text] [Related]
36. Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy.
Shi DD; Arnaout O; Bi WL; Buchbinder EI; Cagney DN; Insco ML; Liu D; Schoenfeld JD; Aizer AA
World Neurosurg; 2020 Jul; 139():226-231. PubMed ID: 32330622
[TBL] [Abstract][Full Text] [Related]
37. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors.
Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW
J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710
[TBL] [Abstract][Full Text] [Related]
38. Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment.
Trommer-Nestler M; Marnitz S; Kocher M; Rueß D; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Jablonska K; Celik E; Ruge MI; Baues C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205431
[TBL] [Abstract][Full Text] [Related]
39. Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy.
Andring L; Squires B; Seymour Z; Fahim D; Jacob J; Ye H; Marvin K; Grills I
Int J Neurosci; 2023 Feb; 133(2):186-193. PubMed ID: 33685315
[TBL] [Abstract][Full Text] [Related]
40. Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional Analysis.
Prabhu RS; Press RH; Patel KR; Boselli DM; Symanowski JT; Lankford SP; McCammon RJ; Moeller BJ; Heinzerling JH; Fasola CE; Asher AL; Sumrall AL; Buchwald ZS; Curran WJ; Shu HG; Crocker I; Burri SH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):459-467. PubMed ID: 28871997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
